P450 enzyme expression patterns in the NCI human tumor cell line panel

Drug Metabolism and Disposition

Volumn 29, Issue 3, 2001, Pages 304-312

  Yu, L J ^a   Matias, J ^a   Scudiero, D A ^a   Hite, K M ^a   Monks, A ^a   Sausville, E A ^a   Waxman, D J ^a  

^a Boston University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARACEMIDE; CARMETHIOZOLE; CHLORAMBUCIL; COUMARIN 7 HYDROXYLASE; CYCLOPHOSPHAMIDE; CYTOCHROME P450; FLUDARABINE PHOSPHATE; FLURORODOPAN; IFOSFAMIDE; MELPHALAN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE; TIOGUANINE; UNCLASSIFIED DRUG; URAMUSTINE;

ARTICLE; CANCER CELL CULTURE; CELL ISOLATION; DRUG INACTIVATION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME METABOLISM; ENZYME SPECIFICITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

7-ALKOXYCOUMARIN O-DEALKYLASE; ALKYLATION; ANTINEOPLASTIC AGENTS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP2B1; CYTOCHROME P-450 ENZYME SYSTEM; DRUG EVALUATION, PRECLINICAL; HUMANS; ISOENZYMES; MICROSOMES; MIXED FUNCTION OXYGENASES; NADPH-FERRIHEMOPROTEIN REDUCTASE; NATIONAL INSTITUTES OF HEALTH (U.S.); NEOPLASMS; TUMOR CELLS, CULTURED; UNITED STATES;

EID: 0035111995     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Expression of cytochromes P450 2E1, 3A4 and 1A1/1A2 in growing and confluent human HepG2 hepatoma cells: Effect of ethanol
2. Generation of a drug resistance profile by quantitation of mdr-1/P- glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen
3. Using the national cancer institute anticancer drug screen to assess the effect of MRP expression on drug sensitivity profiles
4. Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen
5. Catalytic assays for human cytochrome P450
6. Differential activation of cyclophosphamide and ifosphamide by cytochromes P450 2B and 3A in human liver microsomes
7. An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy
8. Complete reversal by thaliblastine of 490-fold Adriamycin resistance in multidrug-resistant (MDR) human breast cancer cells. Evidence that multiple biochemical changes in MDR cells need not correspond to multiple functional determinants for drug resistance
9. Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P450 gene transfer: Development of a combined chemotherapy/cancer gene therapy strategy
10. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene
11. Reductase enzyme expression across the National Cancer Institute tumor cell line panel: Correlation with sensitivity to mitomycin C and EO9
12. Expression of cytochromes P450 in human breast tissue and tumors
13. Polymorphic human cytochrome P450 enzymes: An opportunity for individualized drug treatment
14. Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy
15. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: Implications for drug interactions
16. Interaction of anticancer drugs with hepatic monooxygenase enzymes
17. Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen
18. The NCI anti-cancer drug screen: A smart screen to identify effectors of novel targets
19. Cytochrome P450 CYP3A in human renal cell cancer
20. Expression of cytochrome P450s and glutathione S-transferases in human esophagus with squamous-cell carcinomas
21. Cytochrome P450 and the individuality of species
22. Cytochrome P450 superfamily: Update on new sequences, gene mapping, accession numbers, and nomenclature
23. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents
24. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: Development of mean graph and COMPARE algorithm
25. Human cytochrome P450 enzymes: A status report summa-rizing their reactions, substrates, inducers, and inhibitors
26. Systematic variation in gene expression patterns in haman cancer cell lines
27. Development of a substrate-activity based approach to identify the major haman liver P450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P450 profiles
28. Metabolism and pharmacokinetic behavior of cyclophosphamide and related oxazaphosphorines
29. Regulation of cytochrome P450 gene expression in human colon and breast tumour xenografts
30. Class 1 and class 3 aldehyde dehydrogenase levels in the human tumor cell lines currently used by the National Cancer Institute to screen for potentially useful antitumor agents
31. IAP-family protein suvivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs
32. Glutathione-associated enzymes in the human cell lines of the National Cancer Institute Drug Screening Program
33. Use of the Kohonen self-organizing map to study the mechanisms of action of chemotherapeutic agents
34. P450 gene induction by structurally diverse xenochemicals: Central role of nuclear receptors CAR, PXR, and PPAR
35. Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s
36. An inrormation-intensive approach to the molecular pharmacology of cancer